[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Drug and Device Product Approvals for February 1995

                      ***ORIGINAL AND SUPPLEMENTAL NDAs***
                             FOR NEW DRUG PRODUCTS

19-797     NULYTELY-FLAVORED       BRAINTREE            POLYETHYLENE GLYCOL 3350
18-NOV-94  (POWDER                 BRAINTREE, MA           420GM/BOT
(SUPPL-002)FOR RECONSTITUTION)     02184                   POTASSIUM CHLORIDE
                                                           1.48GM/BOT
                                                           SODIUM BICARBONATE
                                                           5.72GM/BOT
                                                           SODIUM CHLORIDE
                                                           11.2GM/BOT
                                                       (GASTROINTESTINAL LAVAGE)

20-356     NISOCOR                 MILES                   NISOLDIPINE
02-FEB-95  (TABLET,                WEST HAVEN, CT          10MG
(1 S)      EXTENDED RELEASE)       06516                   20MG
                                         
                  30MG
                                                           40MG
                                                           (CALCIUM ION INFLUX
                                                           INHIBITOR)
                                                           [TREATMENT OF                                                                                                                                                                                        
                                                           HYPERTENSION]

20-371     CARDURA                 PFIZER                  DOXAZOSIN MESYLATE
06-FEB-95  (TABLET)                NEW YORK, NY            EQ 1MG BASE
(6 S)                              10017                   EQ 2MG BASE
                                                           EQ 4MG BASE
                                                           EQ 8MG BASE
                                                         (ALPHA-1 ADRENORECEPTOR               
                                              
                                                           BLOCKER)
                                                           [TREATMENT OF BENIGN
                                                          PROSTATIC HYPERPLASIA]

09-218     COUMADIN                DUPONT MERCK            WARFARIN SODIUM
07-FEB-95  (INJECTABLE)            WILMINGTON, DE          5MG/VIAL
(SUPPL-077)                        19880                   (ANTICOAGULANT)

19-643     MEVACOR                 MERCK                   LOVASTATIN
08-FEB-95  (TABLET)                WEST POINT, PA          10MG
(SUPPL-034)                        19486                   20MG                
                                                           40MG
                                                           (NEW INDICATION --
                                                         TO SLOW THE PROGRESSION 
                                                           OF CORONARY                    
                                                                                                                   
                                                           ATHEROSCLEROSIS
                                                       IN PATIENTS WITH CORONARY
                                                           HEART DISEASE)
                
19-816     ORUVAIL                 WYETH AYERST            KETOPROFEN
08-FEB-95  (CAPSULE,               RADNOR, PA              100MG
(SUPPL-001)EXTENDED RELEASE)       19087                   150MG
                                                           (NEW STRENGTHS)

20-500     MEPRON                  BURROUGHS WELLC         ATOVAQUONE
08-FEB-95  (SUSPENSION)            RES TRIANGLE PK, NC     750MG/5ML
(3 P)                              27709                   (ANTIPROTOZOAL)
                                                           [TREATMENT OF MILD TO
                                                           MODERATE PNEUMOCYSTIS
         
                                                  CARINII PNEUMONIA IN
                                                           PATIENTS WHO ARE 
                                                           INTOLERANT TO
                                                           TRIMETHOPRIM-
                                                           SULFAMETHOXAZOLE]

19-452     DERMA-SMOOTHE/FS        HILL DERMAC            FLUOCINOLONE ACETONIDE
16-FEB-95  (OIL)                   ORLANDO, FL             0.01%
(SUPPL-010)                        32814                   (NEW INDICATION --
                                                         PSORIASIS OF THE SCALP)
            
17-806     THALLOUS                DUPONT               THALLOUS CHLORIDE,TL-201
24-FEB-95  CHLORIDE TL 201         WILMINGTON, DE          1MCI/ML
(SUPPL-022)(INJECTABLE)            19880                   (NEW INDICATION --
                                                           SINGLE PHOTON
                                   
                        EMISSION COMPUTED 
                                                           TOMOGRAPHY [SPECT])

50-517     MEFOXIN                 MSD                     CEFOXITIN SODIUM
28-FEB-95  (INJECTABLE)            WEST POINT, PA          EQ 1GM BASE/VIAL
(SUPPL-029)                        19486                   EQ 2GM BASE/VIAL
                                                           EQ 10GM BASE/VIAL
                                                          (NEW DOSAGE REGIMEN --
                                                          DELETION OF THREE DOSE
                                                        REGIMEN FOR PROPHYLACTIC
                                                      USE IN PATIENTS UNDERGOING
                                                           CESAREAN SECTION)

50-581     MEFOXIN                 MSD                     CEFOXITIN SODIUM
28-FEB-95  IN PLASTIC CONTAINER    WEST POINT, PA          EQ 20MG BASE/ML
(SUPPL-017)(INJECTABLE)            19486   
                EQ 40MG BASE/ML
                                                          (NEW DOSAGE REGIMEN --
                                                          DELETION OF THREE-DOSE
                                                        REGIMEN FOR PROPHYLACTIC
                                                      USE IN PATIENTS UNDERGOING
                                                           CESAREAN SECTION)

50-662     BIAXIN                  ABBOTT                  CLARITHROMYCIN
28-FEB-95  (TABLET)                ABBOTT PARK, IL         250MG
(SUPPL-004)                        60064                   500MG
                                                           (NEW INDICATION --
                                                       ACUTE MAXILLARY SINUSITIS
                                                           DUE TO HAEMOPHILUS
                                                         INFLUENZAE OR MORAXELLA
                                                           CATARRHAL
IS)

                         ***APPROVABLE ORIGINAL NDAs***


An approvable letter indicates that FDA is prepared to approve the application
upon the satisfaction of conditions specified in the approvable letter.  

Drug products which are the subject of approvable letters may not be legally
marketed until the firm has satisfied the identified deficiencies, as well as
any other requirements that may be imposed by FDA, and has been notified in
writing that the application has been approved.  Further information on
approvable NDAs is not subject to Freedom of Information (FOI) release until
applications are approved.

20-313     MIACALCIN               SANDOZ                  CALCITONIN, SALMON
10-FEB-95  (SPRAY, METERED)        EAST HANOVER, NJ        200IU/INH
                                   07936                   (POLYPEPTIDE HORMONE)
                                                           [POSTMENOPAUSAL 
                                                           OSTEOPOROSIS]

20-377     CORDARONE 
              WYETH AYERST            AMIODARONE HCL
10-FEB-9   (INJECTABLE)            PHILADELPHIA, PA        50MG/ML
                                   19101                   (ANTIARRHYTHMIC)

20-406     PREVACID                TAP                     LANSOPRAZOLE
14-FEB-95  (CAPSULE,               DEERFIELD, IL           15MG
           DELAYED RELEASE)        60015                   30MG
                                                           (GASTRIC ACID
                                                           SECRETION INHIBITOR)

50-711     ZITHROMAX               PFIZER                 AZITHROMYCIN DIHYDRATE
14-FEB-95  (TABLET)                GROTON, CT              EQ 250MG BASE
                                   06340                 (ANTIBIOTIC, MACROLIDE)

19-835     CETIRIZINE HCL          PFIZER               CETIRIZINE HYDROCHLORIDE
21-FEB-95  (TABLET)                NEW YORK, NY            5MG
                                   10017                   10MG
                             
                              (ANTIHISTAMINE)


                        ***ORIGINAL ABBREVIATED NDAs***

64-103     DAUNORUBICIN HCL        CETUS BEN VENUE    DAUNORUBICIN HYDROCHLORIDE
03-FEB-95  (INJECTABLE)            EMERYVILLE, CA          EQ 20MG BASE/VIAL
                                   94608                 (ANTIBIOTIC, ANTITUMOR)

74-163     NAPROXEN                DANBURY PHARMA          NAPROXEN
10-FEB-95  (TABLET)                DANBURY, CT             250MG
                                   06810                   375MG
                                                           500MG
                                                           (NONSTEROIDAL
                                                           ANTI-INFLAMMATORY)

74-292     DOBUTAMINE HCL          SANOFI WINTHROP      DOBUTAMINE HYDROCHLORIDE
16-FEB-95  (INJECTABLE)            NEW YORK, NY            EQ 12.5MG BASE/ML
                                   10016                   (SYMPATHOMIMETIC/
                             
                         BETA-1 ADRENERGIC AGONIST)

74-452     GEMFIBROZIL             MYLAN                   GEMFIBROZIL
16-FEB-95  (TABLET)                MORGANTOWN, WV          600MG
                                   26504                   (ANTIHYPERLIPIDEMIC)

74-098     DOBUTAMINE HCL          ASTRA                DOBUTAMINE HYDROCHLORIDE
21-FEB-95  (INJECTABLE)            WESTBOROUGH, MA         EQ 12.5MG BASE/ML
                                   01581                   (SYMPATHOMIMETIC/
                                                      BETA-1 ADRENERGIC AGONIST)

74-127     ATENOLOL                MARTEC                  ATENOLOL
21-FEB-95  (TABLET)                KANSAS CITY, MO         50MG
                                   64120                   100MG
                                                       (BETA ADRENERGIC BLOCKER)

74-120     ATENOLOL                COPLEY PHARM            ATENOLOL
24-FEB-95  (TABLET)                CANTON, MA              50MG
                          
         02021                   100MG
                                                       (BETA ADRENERGIC BLOCKER)

72-934     FLUOCINONIDE            FOUGERA                 FLUOCINONIDE
27-FEB-95  (SOLUTION)              MELVILLE, NY            0.05%
                                   11747                   (CORTICOSTEROID)

73-106     ACETAMINOPHEN           ABLE                    ACETAMINOPHEN
27-FEB-95  (SUPPOSITORY)           BALTIMORE, MD           120MG
                                   21224                   (ANALGESIC)
                                                               (OTC)

73-107     ACETAMINOPHEN           ABLE                    ACETAMINOPHEN
27-FEB-95  (SUPPOSITORY)           BALTIMORE, MD           325MG
                                   21224                   (ANALGESIC)
                                                               (OTC)

73-108     ACETAMINOPHEN           ABLE                    ACETAMINOPHEN
27-FEB-95  (SUPPOSITORY)           BALTIMORE, MD          
 650MG
                                   21224                   (ANALGESIC)
                                                               (OTC)

74-166     TOPOSAR                 PHARMACIA               ETOPOSIDE
27-FEB-95  (INJECTABLE)            COLUMBUS, OH            20MG/ML
                                   43216                   (ANTINEOPLASTIC)

74-223     GLIPIZIDE               WATSON LABS             GLIPIZIDE
27-FEB-95  (TABLET)                CORONA, CA              5MG
                                   91720                   10MG
                                                       (BLOOD GLUCOSE REGULATOR)

74-437     PINDOLOL                ROYCE LABS              PINDOLOL
27-FEB-95  (TABLET)                MIAMI, FL               5MG
                                   33014                   10MG
                                                       (BETA ADRENERGIC BLOCKER)
                            
40-082     HEPARIN LOCK FLUSH      SANOFI WINTHROP         HEPARIN SODIUM
28-FEB
-95  (INJECTABLE)            NEW YORK, NY            10 UNITS/ML
                                   10016                   100 UNITS/ML
                                                           (ANTICOAGULANT)

40-089*    ACETAZOLAMIDE SODIUM    BEDFORD                 ACETAZOLAMIDE SODIUM
28-FEB-95  (INJECTABLE)            BEDFORD, OH             EQ 500MG BASE/VIAL
                                   44146                   (CARBONIC ANHYDRASE
                                                           INHIBITOR)

* - First Time Product Available Generically

63-336     DOXORUBICIN HCL         PHARMACHEMIE (NL)   DOXORUBICIN HYDROCHLORIDE
28-FEB-95  (INJECTABLE)            HAARLEM, NETHERLANDS    2MG/ML
                                                           200MG/100ML
                                                         (ANTIBIOTIC, ANTITUMOR)

73-306*    CLOTRIMAZOLE            LEMMON                  CLOTRIMAZOLE
28-FEB-95  (SOLUTION)              SELLERSVILLE, PA        1%
                       
            18960                   (ANTIFUNGAL)

74-111     NAPROXEN                ZENITH LABS             NAPROXEN
28-FEB-95  (TABLET)                NORTHVALE, NJ           250MG
                                   07647                   375MG
                                                           500MG
                                                           (NONSTEROIDAL
                                                           ANTI-INFLAMMATORY)

74-365     CIMETIDINE              LEMMON                  CIMETIDINE
28-FEB-95  (TABLET)                SELLERSVILLE, PA        200MG
                                   18960                   300MG
                                                           400MG
                                                           800MG
                                                           (HISTAMINE 
                                                         H2-RECEPTOR ANTAGONIST)
* - First Time Product Available Generically


     ***ORIGINAL ABBREVIATED A
ND 505(b)(2) NDAs WITH TENTATIVE APPROVAL***

A tentative approval indicates that FDA has given an abbreviated new drug
application (ANDA) or 505(b)(2) application provisional approval under the
terms of the Drug Price Competition and Patent Term Restoration Act.  Such drug 
products that are the subjects of tentative approvals may not be legally
marketed until the market exclusivity and/or patent term of the listed
reference drug product has expired.  Final approval is also contingent upon
conditions and information available to FDA remaining acceptable.  When the 
application receives final approval, the product may be legally marketed.  The
effective approval date will be listed in this publication and in the "Approved
Drug Products with Therapeutic Equivalence Evaluations" list published by FDA.  
Additional information on these applications will become available to the
public when the applications receive final approval.

74-047     ZIDOVUDINE              BARR                    ZIDOVUDINE
24-FEB-95  (C
APSULE)               POMONA, NY              100MG
                                   10970                   (ANTIVIRAL)


                  ***LABELING SUPPLEMENTS TO ORIGINAL NDAs***

17-970     NOLVADEX                ZENECA PHARMS           TAMOXIFEN CITRATE
01-FEB-95  (TABLET)                WILMINGTON, DE          EQ 10MG BASE
                                   19850                   (LABELING REVISION --
                                                           WARNINGS)                   

20-055     GLYBURIDE (MICRONIZED)  HOECHST ROUSSEL         GLYBURIDE
01-FEB-95  (TABLET)                SOMERVILLE, NJ          1.5MG
                                   08876                   3MG
                                                           (LABELING REVISION --
                                                         DELETION OF TRADE NAME;
                                                       DESCRIPTION; PRECAUTIONS;
                                                           ADVERSE REACTIONS;
                                                      DOSAGE AND ADMINISTRATION;
                                                           HOW SUPPLIED)

18-303     LOPRESSOR HCT 50/25     CIBA                    HYDROCHLOROTHIAZIDE
02-FEB-95  (TABLET)                SUMMIT, NJ              25MG
                                   07901                   METOPROLOL TARTRATE
                                                           50MG
                                                           (LABELING REVISION --
                                                       DESCRIPTION; PRECAUTIONS)
                                                                      
18-303     LOPRESSOR HCT 100/25    CIBA                    HYDROCHLOROTHIAZIDE
02-FEB-95  (TABLET)                SUMMIT, NJ              25MG
                                   07901                   METOPROLOL TARTRATE
                                                           100MG
                                                           (LA
BELING REVISION --
                                                       DESCRIPTION; PRECAUTIONS)
       
18-303     LOPRESSOR HCT 100/50    CIBA                    HYDROCHLOROTHIAZIDE
02-FEB-95  (TABLET)                SUMMIT, NJ              50MG
                                   07901                   METOPROLOL TARTRATE
                                                           100MG
                                                           (LABELING REVISION --
                                                       DESCRIPTION; PRECAUTIONS)
            
19-508     AXID                    ELI LILLY               NIZATIDINE
02-FEB-95  (CAPSULE)               INDIANAPOLIS, IN        150MG
                                   46285                   300MG                   
                                                           (LABELING REVISION --
                                                           PRECAUTIONS;
                                                           ADVERSE REACTIONS;
    
                                                       HOW SUPPLIED)

17-553     PROGESTASERT            ALZA                    PROGESTERONE
03-FEB-95  (INSERT,                PALO ALTO, CA           38MG
           EXTENDED RELEASE)       94303                   (LABELING REVISION --
                                                           STD STATEMENT;
                                                         PATIENT PACKAGE INSERT)

20-071     DESOGEN                 ORGANON                 DESOGESTREL
03-FEB-95  (TABLET-28 DAY)         WEST ORANGE, NJ         0.15MG
                                   07052                   ETHINYL ESTRADIOL
                                                           0.03MG
                                                           (LABELING REVISION --
                                                           STD STATEMENT;                                                                                                                                    
              
                                             PRECAUTIONS;
                                                         PATIENT PACKAGE INSERT)

17-997     ULTRALENTE INSULIN      NOVO NORDISK            INSULIN ZINC SUSP 
06-FEB-95  (INJECTABLE)            PRINCETON, NJ           EXTENDED BEEF
                                   08540                   100 UNITS/ML
                                                           (LABELING REVISION --
                                                       LETTER INFORMING PATIENTS
                                                           OF IMMEDIATE                                                                                                                                      
                                                           DISCONTINUATION
                                                           OF THIS PRODUCT) 

19-668     CARDURA                 PFIZER LABS             DOXAZOSIN MESYLATE
06-FEB-95  (TABLET)                NEW YORK, NY            EQ 
1MG BASE
                                   10017                   EQ 2MG BASE
                                                           EQ 4MG BASE
                                                           EQ 8MG BASE
                                                           (LABELING REVISION --
                                                          CLINICAL PHARMACOLOGY;
                                                          INDICATIONS AND USAGE;
                                                          WARNINGS; PRECAUTIONS;
                                                           ADVERSE REACTIONS;
                                                           OVERDOSAGE;
                                                      DOSAGE AND ADMINISTRATION)                   

50-558     ZINACEF                 GLAXO                   CEFUROXIME SODIUM
06-FEB-95  (INJECTABLE)            RES TRIANGLE PK, NC     EQ 750MG BASE/VIAL
                                   27709                   EQ 1.5GM BASE/
VIAL
                                                           EQ 7.5GM BASE/VIAL
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS)

50-643     ZINACEF                 GLAXO                   CEFUROXIME SODIUM
06-FEB-95  IN PLASTIC CONTAINER    RES TRIANGLE PK, NC     EQ 15MG BASE/ML
           (INJECTABLE)            27709                   EQ 30MG BASE/ML
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS)

09-218     COUMADIN                DUPONT MERCK            WARFARIN SODIUM
07-FEB-95  (INJECTABLE)            WILMINGTON, DE          5MG/VIAL
                                   19880                   (LABELING REVISION --
                                                           DESCRIPTION;
                                                          CLINICAL PHARMACOLOGY;
                 
                                          DOSAGE AND LABORATORY
                                                          CONTROL; HOW SUPPLIED)

09-218     COUMADIN                DUPONT MERCK            WARFARIN SODIUM
07-FEB-95  (TABLET)                WILMINGTON, DE          1MG
                                   19880                   2MG
                                                           2.5MG
                                                           4MG
                                                           5MG
                                                           7.5MG
                                                           10MG
                                                           (LABELING REVISION --
                                                           DESCRIPTION;
                                                          CLINICAL PHARMACOLOGY;
                                                           DOSAGE AND LABORATORY
                                          
                CONTROL; HOW SUPPLIED)

14-214     NEGGRAM                 SANOFI WINTHROP         NALIDIXIC ACID
07-FEB-95  (TABLET)                NEW YORK, NY            250MG
                                   10016                   500MG
                                                           1GM
                                                           (LABELING REVISION --
                                                          INDICATIONS AND USAGE;
                                                           PRECAUTIONS;
                                                           ANIMAL PHARMACOLOGY)

17-430     NEGGRAM                 SANOFI WINTHROP         NALIDIXIC ACID
07-FEB-95  (SUSPENSION)            NEW YORK, NY            250MG/5ML
                                   10016                   (LABELING REVISION --
                                                          INDICATIONS AND USAGE;
                                                           PRECAUTIONS;
                         
                                  ANIMAL PHARMACOLOGY)

13-553     ESIMIL                  CIBA                 GUANETHIDINE MONOSULFATE
08-FEB-95  (TABLET)                SUMMIT, NJ              10MG
                                   07901                   HYDROCHLOROTHIAZIDE
                                                           25MG
                                                           (LABELING REVISION --
                                                           PRECAUTIONS)

17-962     PARLODEL                SANDOZ                 BROMOCRIPTINE MESYLATE
08-FEB-95  (TABLET)                EAST HANOVER, NJ        EQ 2.5MG BASE
                                   07936                   EQ 5MG BASE
                                                           (LABELING REVISION --
                                                           CONTRAINDICATIONS;
                                                           WARNINGS)
                   
18-754     ORUDIS                  WYETH AYERST      
      KETOPROFEN
08-FEB-95  (CAPSULE)               PHILADELPHIA, PA        25MG
                                   19101                   50MG
                                                           75MG
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS)

19-643     MEVACOR                 MERCK                   LOVASTATIN
08-FEB-95  (TABLET)                WEST POINT, PA          10MG
                                   19486                   20MG
                                                           40MG
                                                           (LABELING REVISION --
                                                          CLINICAL PHARMACOLOGY;
                                                          INDICATIONS AND USAGE)

19-715     DIPENTUM                PHARMACIA               OLSALAZINE SODIUM
08-FEB-95  (CAPSULE)               COLUMBUS, OH            250MG
       
                            43216                   (LABELING REVISION --
                                                           ADVERSE REACTIONS)

19-816     ORUVAIL                 WYETH AYERST            KETOPROFEN
08-FEB-95  (CAPSULE,               RADNOR, PA              200MG
           EXTENDED RELEASE)       19087                   (LABELING REVISION --
                                                           ADVERSE REACTIONS)

20-098     MIVACRON                BURROUGHS WELLC         MIVACURIUM CHLORIDE
08-FEB-95  (INJECTABLE)            RES TRIANGLE PK, NC     EQ 2MG BASE/ML
                                   27709                   (LABELING REVISION --
                                                           ADVERSE REACTIONS)

20-098     MIVACRON                BURROUGHS WELLC         MIVACURIUM CHLORIDE
08-FEB-95  IN DEXTROSE 5%          RES TRIANGLE PK, NC     EQ 0.5MG BASE/ML
           IN PLASTIC CONTAINER    27709                   EQ 50MG BASE/100ML
           (INJECTABLE)       
                             (LABELING REVISION -- 
                                                           ADVERSE REACTIONS)                                                                 

50-664     CEFZIL                  BRISTOL MYERS SQUIBB    CEFPROZIL
08-FEB-95  (TABLET)                WALLINGFORD, CT         250MG
                                   06492                   500MG
                                                           (LABELING REVISION -- 
                                                           DESCRIPTION;
                                                           ADVERSE REACTIONS;
                                                           HOW SUPPLIED)

50-665     CEFZIL                  BRISTOL MYERS SQUIBB    CEFPROZIL
08-FEB-95  (POWDER                 WALLINGFORD, CT         125MG/5ML
           FOR RECONSTITUTION)     06492                   250MG/5ML
                                                           (LABELING REVISION --
                                   
                        DESCRIPTION;
                                                           ADVERSE REACTIONS;
                                                           HOW SUPPLIED) 

17-450     MONISTAT 7              ORTHO PHARM             MICONAZOLE NITRATE
09-FEB-95  (CREAM)                 RARITAN, NJ             2%
                                   08869                   (LABELING REVISION --
                                                           PATIENT LABELING)
                                                               (OTC)

19-450     VELOSULIN HUMAN         NOVO NORDISK            INSULIN SEMISYNTHETIC
09-FEB-95  (INJECTABLE)            PRINCETON, NJ           PURIFIED HUMAN
                                   08540                   100 UNITS/ML
                                                           (LABELING REVISION --
                                                           PATIENT LABELING)
                                                               (OTC)

18-230     
MYCELEX-7               MILES                   CLOTRIMAZOLE 
13-FEB-95  (CREAM)                 W HAVEN, CT             1%
                                   06516                   (LABELING REVISION --
                                                           PATIENT LABELING)
                                                               (OTC)

50-405     KEFLEX                  ELI LILLY               CEPHALEXIN
13-FEB-95  (CAPSULE)               INDIANAPOLIS, IN        EQ 250MG BASE
                                   46285                   EQ 500MG BASE
                                                           (LABELING REVISION --
                                                          CLINICAL PHARMACOLOGY)

50-406     KEFLEX                  ELI LILLY               CEPHALEXIN
13-FEB-95  (POWDER                 INDIANAPOLIS, IN        EQ 125MG BASE/5ML
           FOR RECONSTITUTION)     46285                   EQ 250MG BASE/5ML
                                                           (LABELING 
REVISION --
                                                          CLINICAL PHARMACOLOGY)        

06-309     KWELL                   REED AND CARNRICK       LINDANE
16-FEB-95  (CREAM)                 JERSEY CITY, NJ         1%
                                   07302                   (LABELING REVISION --
                                                          WARNINGS; PRECAUTIONS;
                                                           CONTRAINDICATIONS;
                                                           ADVERSE REACTIONS;
                                                           DIRECTIONS FOR USE)

06-309     KWELL                   REED AND CARNRICK       LINDANE
16-FEB-95  (LOTION)                JERSEY CITY, NJ         1%
                                   07302                   (LABELING REVISION --
                                                          WARNINGS; PRECAUTIONS;
                                                           CONTRAINDICATIONS;
                          
                                 ADVERSE REACTIONS;
                                                           DIRECTIONS FOR USE)

10-718     KWELL                   REED AND CARNRICK       LINDANE
16-FEB-95  (SHAMPOO)               JERSEY CITY, NJ         1%
                                   07302                   (LABELING REVISION --
                                                           WARNINGS; 
                                                           PRECAUTIONS;
                                                           CONTRAINDICATIONS;
                                                           ADVERSE REACTIONS;
                                                           DIRECTIONS FOR USE)

19-452     DERMA-SMOOTHE/FS        HILL DERMAC            FLUOCINOLONE ACETONIDE
16-FEB-95  (OIL)                   ORLANDO, FL             0.01%
                                   32814                   (LABELING REVISION --
                                                          INDICATIONS AND USA
GE)

19-766     ZOCOR                   MERCK                   SIMVASTATIN
16-FEB-95  (TABLET)                WEST POINT, PA          5MG
                                   19486                   10MG
                                                           20MG
                                                           40MG
                                                           (LABELING REVISION --
                                                      DOSAGE AND ADMINISTRATION)

20-090     DIFLUCAN                PFIZER                  FLUCONAZOLE
21-FEB-95  (POWDER FOR             NEW YORK, NY            50MG/5ML
           RECONSTITUTION)         10017                   200MG/5ML
                                                           (LABELING REVISION --
                                                          CLINICAL PHARMACOLOGY;
                                                           PRECAUTIONS;
                                                           ADVERSE REACTIONS;
          
                                            DOSAGE AND ADMINISTRATION)

07-883     ANTABUSE                WYETH AYERST            DISULFIRAM
21-FEB-95  (TABLET)                PHILADELPHIA, PA        250MG
                                   19101                   500MG
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS)
            
50-162     CLEOCIN HCL             UPJOHN              CLINDAMYCIN HYDROCHLORIDE
21-FEB-95  (CAPSULE)               KALAMAZOO, MI           EQ 75MG BASE
                                   49001                   EQ 150MG BASE
                                                           EQ 300MG BASE
                                                           (LABELING REVISION --
                                                           WARNINGS; ADVERSE                                                                                                                            
     
                                                           REACTIONS)
                   
50-441     CLEOCIN PHOSPHATE       UPJOHN                  CLINDAMYCIN PHOSPHATE
21-FEB-95  (INJECTABLE)            KALAMAZOO, MI           EQ 150MG BASE/ML
                                   49001                   (LABELING REVISION --
                                                           WARNINGS; ADVERSE                                                                                                                                 
                                                           REACTIONS)

50-639     CLEOCIN PHOSPHATE       UPJOHN                  CLINDAMYCIN PHOSPHATE
21-FEB-95  IN DEXTROSE 5%          KALAMAZOO, MI           EQ 6MG BASE/ML
           IN PLASTIC CONTAINER    49001                   EQ 12MG BASE/ML
           (INJECTABLE)                                    EQ 18MG BASE/ML
                                                           (LABELING REVISION --
                           
                                WARNINGS; ADVERSE                                                                                                                                 
                                                           REACTIONS)

17-920     TAGAMET                 SMITHKLINE BEECHAM      CIMETIDINE
22-FEB-95  (TABLET)                PHILADELPHIA, PA        200MG
                                   19101                   300MG
                                                           400MG
                                                           800MG
                                                           (LABELING REVISION --
                                                       DESCRIPTION; PRECAUTIONS;
                                                           ADVERSE REACTIONS;
                                                           HOW SUPPLIED)
                
17-924     TAGAMET                 SMITHKLINE BEECHAM   CIMETIDINE HYDROCHLORIDE
22-FEB-95  (SOLUTION)            
  PHILADELPHIA, PA        EQ 300MG BASE/5ML
                                   19101                   (LABELING REVISION --
                                                       DESCRIPTION; PRECAUTIONS;
                                                           ADVERSE REACTIONS;
                                                           HOW SUPPLIED)

17-939     TAGAMET                 SMITHKLINE BEECHAM   CIMETIDINE HYDROCHLORIDE
22-FEB-95  (INJECTABLE)            PHILADELPHIA, PA        EQ 300MG BASE/2ML
                                   19101                   (LABELING REVISION --
                                                       DESCRIPTION; PRECAUTIONS;
                                                           ADVERSE REACTIONS;
                                                           HOW SUPPLIED)
                                                                   
18-537     TRIDIL                  DUPONT MERCK            NITROGLYCERIN
22-FEB-95  (INJECTABLE)            GARDEN CITY, NY    
     0.5MG/ML
                                   11530                   5MG/ML
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS)

18-780     HUMULIN R               LILLY              INSULIN BIOSYNTHETIC HUMAN
22-FEB-95  (INJECTABLE)            INDIANAPOLIS, IN        100 UNITS/ML
                                   46285                   (LABELING REVISION --
                                                           INFORMATION FOR THE                                                                                                                               
                                                           PATIENT)
                                                               (OTC)

18-781     HUMULIN N               LILLY                   INSULIN SUSP ISOPHANE
22-FEB-95  (INJECTABLE)            INDIANAPOLIS, IN        BIOSYNTHETIC HUMAN
                                   46285       
            100 UNITS/ML
                                                           (LABELING REVISION --
                                                           INFORMATION FOR THE                                                                                                                               
                                                           PATIENT)
                                                               (OTC)

18-841     DAYPRO                  SEARLE                  OXAPROZIN
22-FEB-95  (TABLET)                SKOKIE, IL              600MG
                                   60077                   (LABELING REVISION --
                                                           ADVERSE REACTIONS)

19-377     HUMULIN L               LILLY                   INSULIN ZINC SUSP
22-FEB-95  (INJECTABLE)            INDIANAPOLIS, IN        BIOSYNTHETIC HUMAN
                                   46285                   100 UNITS/ML
                                                     
      (LABELING REVISION --
                                                           INFORMATION FOR THE                                                                  
                                                           PATIENT)
                                                               (OTC)                                                                      

19-434     TAGAMET HCL             SMITHKLINE BEECHAM   CIMETIDINE HYDROCHLORIDE
22-FEB-95  IN SODIUM CHLORIDE 0.9% PHILADELPHIA, PA        EQ 6MG BASE/ML
           IN PLASTIC CONTAINER    19101                   (LABELING REVISION --
           (INJECTABLE)                                DESCRIPTION; PRECAUTIONS;
                                                           ADVERSE REACTIONS;
                                                           HOW SUPPLIED) 

19-558     PRINIVIL                MERCK                   LISINOPRIL
22-FEB-95  (TABLET)                WEST POINT, PA          2.5MG
                                   194
86                   5MG
                                                           10MG
                                                           20MG
                                                           40MG
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS;
                                                      DOSAGE AND ADMINISTRATION)

19-571     HUMULIN U               LILLY              INSULIN ZINC SUSP EXTENDED
22-FEB-95  (INJECTABLE)            INDIANAPOLIS, IN        BIOSYNTHETIC HUMAN
                                   46285                   100 UNITS/ML
                                                           (LABELING REVISION --
                                                           INFORMATION FOR THE                                                                                                                               
                                                
           PATIENT)                                                                                                                                               
                                                               (OTC)

19-717     HUMULIN 70/30           LILLY              INSULIN BIOSYNTHETIC HUMAN
22-FEB-95  (INJECTABLE)            INDIANAPOLIS, IN        30 UNITS/ML
                                   46285                   INSULIN SUSP ISOPHANE
                                                           BIOSYNTHETIC HUMAN
                                                           70 UNITS/ML
                                                           (LABELING REVISION --
                                                           INFORMATION FOR THE                                                                                                                               
                                                           PATIENT)
                                                      
         (OTC)                   

19-778     PRINZIDE 10-12.5        MERCK                   HYDROCHLOROTHIAZIDE
22-FEB-95  (TABLET)                WEST POINT, PA          12.5MG
                                   19486                   LISINOPRIL
                                                           10MG
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS)

19-778     PRINZIDE 20-12.5        MERCK                   HYDROCHLOROTHIAZIDE
22-FEB-95  (TABLET)                WEST POINT, PA          12.5MG
                                   19486                   LISINOPRIL
                                                           20MG
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS)

19-778     PRINZIDE 20-25          MERCK                   HYDROCHLOROTHIAZIDE
22-FEB-95  (TABLET)             
   WEST POINT, PA          25MG
                                   19486                   LISINOPRIL
                                                           20MG
                                                           (LABELING REVISION --
                                                           ADVERSE REACTIONS)            

20-100     HUMULIN 50/50           LILLY              INSULIN BIOSYNTHETIC HUMAN
22-FEB-95  (INJECTABLE)            INDIANAPOLIS, IN        50 UNITS/ML
                                   46285                   INSULIN SUSP ISOPHANE
                                                           BIOSYNTHETIC HUMAN
                                                           50 UNITS/ML
                                                           (LABELING REVISION --
                                                           INFORMATION FOR THE                                                                                                                              
                  
                                         PATIENT)
                                                               (OTC)

18-748     LOPROX                  HOECHST ROUSSEL         CICLOPIROX OLAMINE
23-FEB-95  (CREAM)                 SOMERVILLE, NJ          1%
                                   08766                   (LABELING REVISION --
                                                           PRECAUTIONS)

19-824     LOPROX                  HOECHST ROUSSEL         CICLOPIROX OLAMINE
23-FEB-95  (LOTION)                SOMERVILLE, NJ          1%
                                   08766                   (LABELING REVISION --
                                                           PRECAUTIONS)                  

20-031     PAXIL                   SMITHKLINE BEECHAM   PAROXETINE HYDROCHLORIDE
23-FEB-95  (TABLET)                KING OF PRUSSIA, PA     EQ 20MG BASE
                                   19406                   EQ 30MG BASE
                                                           (LABELING REVI
SION --
                                                           ADVERSE REACTIONS;
                                                           PRECAUTIONS)
                
20-226     NAPHCON-A               ALCON               NAPHAZOLINE HYDROCHLORIDE
23-FEB-95  (SOLUTION)              FORT WORTH, TX          0.025%
                                   76115                   PHENIRAMINE MALEATE
                                                           0.3%
                                                           (LABELING REVISION --
                                                           PATIENT LABELING)
                                                               (OTC)

17-806     THALLOUS                DUPONT              THALLOUS CHLORIDE, TL-201
24-FEB-95  CHLORIDE TL 201         WILMINGTON, DE          1MCI/ML
           (INJECTABLE)            19880                   (LABELING REVISION --
                                                           DESCRIPTION;
                              
                            INDICATIONS AND USAGE;
                                                           PRECAUTIONS;
                                                           ADVERSE REACTIONS;
                                                      DOSAGE AND ADMINISTRATION)

18-086     TIMOPTIC                MERCK                   TIMOLOL MALEATE
24-FEB-95  (SOLUTION/DROPS)        WEST POINT, PA          EQ 0.25% BASE
                                   19486                   EQ 0.5% BASE
                                                           (LABELING REVISION --
                                                          INDICATIONS AND USAGE;
                                                           PRECAUTIONS;
                                                           ADVERSE REACTIONS;
                                                           OVERDOSAGE)

18-751     SPECTAZOLE              JOHNSON RW              ECONAZOLE NITRATE
24-FEB-95  (CREAM)                 RARITAN, NJ             1
%
                                   08869                   (LABELING REVISION --
                                                          CLINICAL PHARMACOLOGY)
                                                                   
50-517     MEFOXIN                 MSD                     CEFOXITIN SODIUM
28-FEB-95  (INJECTABLE)            WEST POINT, PA          EQ 1GM BASE/VIAL
                                   19486                   EQ 2GM BASE/VIAL
                                                           EQ 10GM BASE/VIAL
                                                           (LABELING REVISION --
                                                           DOSAGE)

50-581     MEFOXIN                 MSD                     CEFOXITIN SODIUM
28-FEB-95  IN PLASTIC CONTAINER    WEST POINT, PA          EQ 20MG BASE/ML
           (INJECTABLE)            19486                   EQ 40MG BASE/ML
                                                           (LABELING REVISION --
                               
                            DOSAGE)

50-662     BIAXIN                  ABBOTT                  CLARITHROMYCIN
28-FEB-95  (TABLET)                ABBOTT PARK, IL         250MG
                                   60064                   500MG
                                                           (LABELING REVISION --
                                                          INDICATIONS AND USAGE;
                                                           PRECAUTIONS)

                    ***BIOLOGICAL PRODUCT LICENSES ISSUED***

1180      NONE               CENLA PLASMA               SOURCE PLASMA
15-FEB-95 (NONE)             ROUND ROCK, TX             (FOR FURTHER 
                             78664                      MANUFACTURING USE)
                                                        (A,B)

1181      NONE               INSTITUTO GRIFOLS S A      ALBUMIN (HUMAN)
17-FEB-95 (INJECTABLE)       BARCELONA, SPAIN           (A,B) 

1090      HAVRIX             SMITHKLINE BEECHAM         HEPATITIS A VACC
INE
22-FEB-95 (INJECTABLE)       1330 RIXENSART             (IMMUNIZATION AGAINST
                             BELGIUM                    HEPATITIS A)
                                                        (B)

1177      NONE               MICRO TYPING SYS           BLOOD GROUPING REAGENT
24-FEB-95 (IN-VITRO)         POMPANO BEACH, FL          (B)
                                     33069

(A) Establishment License Issued
(B) Product License Issued


                   ***BIOLOGICAL PRODUCT DEVICE APPROVALS***

BK940040  SEPACELL PLS-4A    BAXTER HLTHCARE            REDUCTION FILTERS FOR
14-FEB-95 AND PLS-10A        ROUND LAKE, IL             PLATELET PRODUCTS
          LEUKOCYTE          60073                      (C)

BK940041  SEPACELL R2000     BAXTER HLTHCARE            LEUKOCYTE REDUCTION
14-FEB-95                    ROUND LAKE, IL             SET FOR RED BLOOD CELLS
                             60073                      (C)

(C) Substantially Equivalent

             ***MEDICAL DEVICE - PREMARKET AP
PROVAL APPLICATIONS***

THE FOLLOWING DATA IS RECEIVED FROM THE CENTER FOR DEVICES AND RADIOLOGICAL
HEALTH AND IS NOT EDITED BY THE DIVISION OF DRUG INFORMATION RESOURCES PRIOR
TO PUBLICATION

P920051  STORZ MODULITH        KARL STORZ ENDOSCOPY-   USE IN NONINVASIVE
02/17/95 LITHOTRIPTER,         AMERICA, INC.           FRAGMENTATION OF
         MODEL SL20            KENNESAW, GA            URINARY CALCULI IN
                                 30144                 THE KIDNEY AND UPPER
                                                       URETER

P930029  ATAKR RADIO           MEDTRONIC CARDIORHYTHM  1)INTERRUPTION OF 
02/09/95 FREQUENCY CATHETER    SAN JOSE, CA            ACCESSORY 
         ABLATION (RFCA)         95134-1806            ATRIOVENTRICULAR (AV)
         SYSTEM-RF ABLATR                              CONDUCTION PATHWAYS
         & RF MARINR SERIES                            ASSOC W/TACHYCARDIA 
         OF RFCA CATHETERS                             (TC) 2)TREATMENT OF
                             
                          AV NODAL REENTRANT TC
                                                       3)CREATION OF COMPLETE
                                                       AV BLOCK

                    ***MEDICAL DEVICE - PMA SUPPLEMENTALS***

THE FOLLOWING DATA IS RECEIVED FROM THE CENTER FOR DEVICES AND RADIOLOGICAL
HEALTH AND IS NOT EDITED BY THE DIVISION OF DRUG INFORMATION RESOURCES PRIOR TO 
PUBLICATION

N16895/S83  OPTIMA                BAUSCH & LOMB           LABELING
02/23/95    (POLYMACON)           ROCHESTER, NY           MODIFICATIONS
            VISIBILITY TINTED       04500
            HYDROPHILIC 
            CONTACT LENSES

N17004/S6   SURGICAL              HOWMEDICA, INC.         CHANGES MADE TO
02/24/95    SIMPLEX P             RUTHERFORD, NJ          PACKAGE INSERT OF THE                    
RADIOPAQUE BONE         07070-2584            DEVICE
            CEMENT 

N180033/S27 ACUVUE                JOHNSON & JOHNSON       ALTERNATE
02/13/95    (ETAFILCON A)         VISION PRODUCTS, 
INC.   MANUFACTURING SITE
            SOFT (HYDROPHILIC)    JACKSONVILLE, FL                                

            CONTACT LENSES          32247                                            


N50510/S57  VITEK SYSTEMS        BIOMERIEUX VITEK, INC.   REMOVAL OF DISCLAIMER  
02/23/95    "GENERAL              HAZELWOOD, MO           FOR PSEUDOMONAS/
            SUSCEPTIBILITY CARD"    63042-2395            CIPROFLOXACIN

P810002/S34 ST. JUDE MEDICAL      ST. JUDE MEDICAL, INC.  REMOVAL OF THE
02/16/95    MECHANICAL HEART      ST. PAUL, MN            MANUFACTURING CHECK
            VALVE                   55117                 SHEET REGARDING THE
                                                          ORIENTATION OF THE
                                                          VALVE IN THE VALVE
                                                          HOLDER

P810031/S18 HEALON                PHARMACIA, INC.         CHANGING FROM THE
02/17/95    VISCOELASTIC          OPHTHALMICS             RABBIT PYROGE
N TEST
            PRODUCTS              MONROVIA, CA            TO THE LIMULUS
                                    91017-7136            AMOEBOCYTE LYSATE
                                                          (LAL) TEST FOR THE
                                                          DETECTION OF
                                                          BACTERIAL ENDOTOXIN

P820021/S24 NEWVUES               CIBA VISION CORPORATION NEW MODEL LABELING
02/13/95    THERAPEUTIC           DULUTH, GA              MODIFICATIONS
            (VIFILCON A)            30136-1518
            SOFT (HYDROPHILIC)  
            CONTACT LENSES

P840039/S47 ULTRAVIOLET (UV)      STORZ OPHTHALMICS, INC. USE OF A NEW LENS
02/08/95    ABSORBING AND         CLEARWATER, FL          CARRIER
            NON-UV ABSORBING        34619
            PMAA INTRAOCULAR 
            LENSES (IOLS)

P840040/S47 MEDI-TECH             BOSTON SCIENTIFIC       THE DEVICE AS
02/23/95    CORONARY BALLOON      CORPORATION             MODIFIED WILL
 BE
            DILATATION            WATERTOWN, MA           MARKETED UNDER THE
            CATHETER -              02172-2414            TRADE NAME:SYNERGY II
            SYNERGY II LONG                               CONVERTIBLE RAPID
            BALLOON                                       EXCHANGE CATHETER
            DILATATION CATHETER  

P850036/S2  BAUSCH & LOMB         BAUSCH & LOMB           FORMULATION
02/23/95    SENSITIVE EYES        ROCHESTER, NY           ADJUSTMENT TO ENHANCE
            LENS LUBRICANT          14692-0450            THE STABILITY AND AN
                                                          ALTERNATE 3 ML SIZE
                                                          BOTTLE

P860002/S16 ULTRAVIOLET (UV)      STORZ OPHTHALMICS, INC. USE OF A NEW LENS
02/08/95    ABSORBING AND         CLEARWATER, FL          CARRIER
            NON-UV ABSORBING        34619 
            PMAA INTRAOCULAR  
            LENSES (IOLS)

P860034/S11 MODELS AC-21          ALLERGAN MEDICAL OPTICS RE
VISED LABELING THAT
02/03/95    NON-ULTRAVIOLET-      IRVINE, CA              CONTAINS 3-YEAR DATA
            ABSORBING AND AC-21B    92718                 FOR MODELS AC-21 &
            ULTRAVIOLET-                                  AC-21B ANTERIOR
            ABSORBING                                     CHAMBER INTRAOCULAR
            ANTERIOR CHAMBER                              LENSES (IOLS)
            INTRAOCULAR LENSES

P870036/S31 VERSAFLEX             MEDTRONIC INTERVENTIONAL APPROVAL FOR THE
02/15/95    BUCHBINDER            VASCULAR                MEDTRONIC FALCON
            OMNIFLEX PTCA         SAN DIEGO, CA           CORONARY BALLOON
            CATHETER SYSTEM -       92121-2256            DILATATION CATHETER
            MEDTRONIC FALCON
            CORONARY BALLOON
            DILATATION CATHETER

P870073/S16 ULTRAVIOLET (UV)      STORZ OPHTHALMICS, INC. USE OF A NEW LENS
02/08/95    ABSORBING AND         CLEARWATER, FL          CARRIER
            NON-UV ABSORBING        34619
            P
MMA INTRAOCULAR
            LENSES (IOLS)

P880079/S13 PURE EYES             CIBA VISION CORPORATION NAME CHANGE & REVISED
02/09/95    CLEANER/RINSE         DULUTH, GA              LABELING FOR SOFTWEAR
                                    30136-1518            PLUS SALINE - THE
                                                          DEVICE WILL BE
                                                          MARKETED UNDER TRADE
                                                          NAME:PURE EYES
                                                          CLEANER/RINSE       
                                                                     
P880090/S16 ULTRAVIOLET (UV)      STORZ OPHTHALMICS, INC. USE OF A NEW LENS
02/08/95    ABSORBING AND         CLEARWATER, FL          CARRIER
            NON-UV ABSORBING        34619 
            PMMA INTRAOCULAR
            LENSES (IOLS)

P890003/S35 MEDTRONIC MINUET      MEDTRONIC, INC.         APPROVAL TO MARKET
02/15/95    PULSE GENERATOR       MINNEAPOLIS, MN    
     THE REFERENCED MODELS
            MODELS 7107 & 7108      55432-3576            OF THE PACEMAKER AS
                                                          THE VITATRON LEGACY D                                                                 

                                                          MODELS 750 & 751

P890056/S1  MODEL PC-28LB         ALLERGAN MEDICAL OPTICS CHANGE STERILIZATION
02/08/95    ULTRAVIOLET-          SANTA ANA, CA           CYCLE TO 100%
            ABSORBING               92799-5155            ETHYLENE OXIDE CYCLE
            POSTERIOR CHAMBER                             WITH A NITROGEN PURGE
            INTRAOCULAR LENS

P900039/S7  COLLAGRAFT BONE       COLLAGEN CORPORATION   PACKAGING MODIFICATIONS
02/14/95    GRAFT MATRIX          PALO ALTO, CA  
                                    94303                                                                                              

P900060/S3  CARBOMEDICS           CARBOMEDICS, INC.       APPROVAL TO UTILIZE  
02/16/95 
   PROSTHETIC HEART      AUSTIN, TX              NEW STEAM STERILIZER
            VALVE                   78752-1793            AND AN ENLARGED
                                                          CONTROLLED
                                                          ENVIRONMENT IN THE
                                                          AUSTIN MANUFACTURING
                                                          FACILITY

P910056/S3  CHIROFLEX II          CHIRON VISION           CHANGE IN HAPTIC PULL
02/17/95    MULTI-PIECE           CORPORATION             TEST
            SILICONE IOLS         IRVINE, CA
                                    92718-1903

P940013/S1  PRECISION UV          PILKINGTON BARNES HIND  ADDITION OF LIGHT
02/09/95    (VASURFILCON)         SUNNYVALE, CA           BLUE LOCATOR TINT & A
            SOFT (HYDROPHILIC)      94086-5200            CONTACT LENS
            CONTACT LENSES                                STABILITY EXTENSION
            FOR EXTENDED WEAR                 
            PROTOCOL & AN
            (CLEAR & TINTED)                              ALTERNATE
                                                          MANUFACTURING SITE

                        ***ORIGINAL VETERINARY NADAs***

           THERE ARE NO ORIGINAL VETERINARY NADAs FOR FEBRUARY 1995.

                  ***ORIGINAL ABBREVIATED VETERINARY NADAs***

     THERE ARE NO ORIGINAL ABBREVIATED VETERINARY NADAs FOR FEBRUARY 1995.



                      ***SUPPLEMENTAL VETERINARY NADAs***

091-582   GILT EDGE TYLAN MIX   CATTLE,     PREMIERE AGRI TECH TYLOSIN PHOSPHATE
07-FEB-95 (PREMIX)              CHICKENS,   FORT WAYNE, IN          20GM/LB
                                SWINE       46801                   
            

Back to Top     Back to Drug and Device Product Approvals

Date created: July 11, 1996; last updated: June 20, 2005

horizonal rule